DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Malignant Urinary System Neoplasm — screening already-approved drugs against its 24-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMalignant Urinary System Neoplasm maps to a 24-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for malignant urinary system neoplasm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
endothelial PAS domain protein 1 (EPAS1) — EPAS1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet furan-2-ylmethyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3H82 · 1.5 Å · ligand N-(furan-2-ylmethyl)-2-nitro-4-(trifluoromethyl)aniline (020). Experimental structure, not a prediction.
What the evidence adds up to
Urothelial bladder cancer is the most common malignant neoplasm in the urinary tract, accounting for 90% of cases, and is the second most common urologic malignancy. Organ-sparing treatment for non-muscle invasive bladder cancer, combined with chemotherapy and immunotherapy, is a standard method; for muscle-invasive tumours, radical surgical treatment in combination with chemotherapy is applied. Bladder cancer in general does not have aggressive characteristics, unlike kidney cancer, which is capable of a lightning-fast course, has a greater ability to metastasise early and can cause death in a short period of time. Malignant neoplasms of the urinary system associated with pregnancy account for less than 1% of oncological pathologies in pregnant women.
Two major routes of developing urothelial carcinoma have been molecularly described. Recurrent genomic abnormalities have been identified in many types of renal cell carcinoma, and some types are specifically defined by the molecular abnormality. Recurrent translocations involving ETS family genes are found in approximately half of prostate cancer cases. Testicular germ cell tumours typically harbour i(12p). Penile neoplasms are often high-risk human papillomavirus-driven cancers. While many genomic abnormalities are not yet clinically relevant, there is an increasing library of ancillary tests that may guide diagnosis, prognosis, and/or treatment of many neoplasms.
The microbiome is emerging as a relevant player in cancer development and progression. A systematic review found 37 studies: prostate cancer 12, bladder cancer 20, kidney cancer 4, penile/testicular cancer 1. These reveal distinct associations specific to each condition, hinting at potential therapeutic avenues and future biomarker discoveries. Exploration of urogenital microorganisms remains limited.
What is still missing is clinical validation of molecular tests for optimal diagnosis, prognosis, and treatment of aggressive malignancies. Further research is imperative to unravel the complexities of the microbiome's role. Treatment and obstetric tactics in each individual case should be personalised and involve a large multidisciplinary team. Various prognostic criteria remain under investigation.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PubMed · 2003 · 35 citations · open access
Molecular pathogenesis of urothelial bladder cancer.
AbstractCarcinoma of the urinary bladder is the second most common urologic malignancy. In addition, these tumors are one of the best understood genitourinary neoplasms with a well defined etiology, natural history, tumor biology, treatment options and outcome. This level of understanding arises as a consequence of multiple factors and represents a convergence of knowledge from diverse scientific disciplines. Insight provided by these disciplines, coupled with unique features of this neoplasm which make it assessable for detection, monitoring and treatment, combine to make this disease a model system for modern oncology. The intent of this review is to provide the reader an overview of our current understanding of this tumor from the standpoint of its molecular biology as related to tumor development and progression.
Archives of Pathology & Laboratory Medicine · 2019 · 9 citations · open access
Practical Molecular Testing in a Clinical Genitourinary Service
AbstractCONTEXT.—: Molecular testing is increasingly playing a key role in the diagnosis, prognosis, and treatment of neoplasms of the genitourinary system. OBJECTIVE.—: To provide a general overview of the clinically relevant molecular tests available for neoplasms of the genitourinary tract. DATA SOURCES.—: Relevant medical literature indexed on PubMed. CONCLUSIONS.—: Understanding of the molecular oncology of genitourinary neoplasms is rapidly advancing, and the pathologist must be aware of the practical implications of molecular testing. While many genomic abnormalities are not yet clinically relevant, there is an increasing library of ancillary tests that may guide diagnosis, prognosis, and/or treatment of many neoplasms. Recurrent genomic abnormalities have been identified in many types of renal cell carcinoma, and some types of renal cell carcinoma are specifically defined by the molecular abnormality. Two major routes of developing urothelial carcinoma have been molecularly described. Recurrent translocations involving ETS family genes are found in approximately half of prostate cancer cases. Testicular germ cell tumors typically harbor i(12p). Penile neoplasms are often high-risk human papillomavirus-driven cancers. Nonetheless, even as genitourinary neoplasms are increasingly better understood at the molecular level, further research with eventual clinical validation is needed for optimal diagnosis, prognosis, and treatment of aggressive malignancies in the genitourinary tract.
The Influence of Microbiome on Urological Malignancies: A Systematic Review
AbstractThe microbiome, once considered peripheral, is emerging as a relevant player in the intricate web of factors contributing to cancer development and progression. These often overlooked microorganisms, in the context of urological malignancies, have been investigated primarily focusing on the gut microbiome, while exploration of urogenital microorganisms remains limited. In light of this, our systematic review delves into the complex role of these understudied actors in various neoplastic conditions, including prostate, bladder, kidney, penile, and testicular cancers. Our analysis found a total of 37 studies, with prostate cancer-12, bladder cancer-20, kidney cancer-4, penile/testicular cancer-1, which reveals distinct associations specific to each condition, hinting at potential therapeutic avenues and future biomarker discoveries. It becomes evident that further research is imperative to unravel the complexities of this domain and provide a more comprehensive understanding.
Seminars in Surgical Oncology · 1997 · 2 citations
Future therapies for the treatment of bladder neoplasms
AbstractThe last several decades have witnessed an exponential growth in the understanding of the biology of human neoplasms. As a consequence, a number of new strategies for the treatment of urologic cancers are currently under evaluation. We provide an overview of promising new treatment approaches as they apply to the management of transitional cell carcinoma of the urinary bladder.
Current clinical urology · 2001 · 1 citations · open access
Biology and Molecular Aspects of Development and Progression of Bladder Cancer
AbstractCarcinoma of the urinary bladder is the second most common urologic malignancy (1). Not only are neoplasms of the urinary bladder of high clinical relevance, but they represent one of the best understood of the genito-urinary (GU) neoplasms. Relative to other tumors, the etiology, natural history, tumor biology, treatment options and outcome for the spectrum of bladder malignancies are well defined. This level of understanding arises as a consequence of multiple factors and represents a convergence of knowledge from diverse scientific disciplines. Insight provided by these disciplines, coupled with unique features of this neoplasm which make it assessable for detection, monitoring and treatment, combine to make this disease a model system for modern oncology.
Malignant tumors of the urinary system associated with pregnancy
AbstractMalignant neoplasms of the urinary system associated with pregnancy are extremely rare and occupy a small part in the overall structure of oncological pathologies in pregnant women and account for less than 1 %, while urinary tract cancer associated with pregnancy proceeds differently. Bladder cancer in general does not have aggressive characteristics, unlike kidney cancer, so its detection and timely treatment is associated with favorable outcomes for both mother and fetus. Kidney cancer, on the contrary, is capable of a lightning-fast course, has a greater ability to metastasize early and can cause death in a short period of time. The article presents clinical observations of patients with various locations of malignant neoplasms of the urinary tract, shows the difficulties of diagnosis, features of the clinical course, treatment and prognosis in this category of patients. It is clearly shown that treatment and obstetric tactics in each individual case should be personalized and involve a large multidisciplinary team of specialists with experience working with this category of patients.
Peculiarities of hemostasisin transurethral resection of prostatic gland using fybrinolysis inhibitor
AbstractUrothelial cancer, in 90 % cases presented as bladder cancer, is the most common malignant neoplasm in urinary tract. Organ-sparing treatment for non-muscle invasive bladder cancer, combined with chemotherapy and immunotherapy, is a standard method, in muscle-invasive tumors radical surgical treatment in combination with chemotherapy is applied. Various prognostic criteria are under investigation now.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
